Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H12ClNO2 |
| Molecular Weight | 213.661 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC[C@@H](CC(O)=O)C1=CC=C(Cl)C=C1
InChI
InChIKey=KPYSYYIEGFHWSV-MRVPVSSYSA-N
InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)/t8-/m1/s1
| Molecular Formula | C10H12ClNO2 |
| Molecular Weight | 213.661 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
12 mg 1 times / day multiple, oral Highest studied dose Dose: 12 mg, 1 times / day Route: oral Route: multiple Dose: 12 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: |
Other AEs: headedness, headache... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| headedness | 1 pt | 12 mg 1 times / day multiple, oral Highest studied dose Dose: 12 mg, 1 times / day Route: oral Route: multiple Dose: 12 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: |
| headache | mild, 1 pt | 12 mg 1 times / day multiple, oral Highest studied dose Dose: 12 mg, 1 times / day Route: oral Route: multiple Dose: 12 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Bidirectional enantioselective effects of the GABAB receptor agonist baclofen in two mouse models of excessive ethanol consumption. | 2015-02 |
|
| Intra-nucleus accumbens shell injections of R(+)- and S(-)-baclofen bidirectionally alter binge-like ethanol, but not saccharin, intake in C57Bl/6J mice. | 2014-10-01 |
|
| Permeation and systemic absorption of R- and S-baclofen across the nasal mucosa. | 2011-07 |
|
| Effects of L-baclofen and D-baclofen on the auditory system: a study of click-evoked potentials from the inferior colliculus in the rat. | 1995-05 |
|
| NMDA receptor antagonists block cardiovascular responses to intrathecal administration of D-baclofen in the rat. | 1992-06-05 |
|
| Modeling of the effect site equilibration kinetics and pharmacodynamics of racemic baclofen and its enantiomers using quantitative EEG effect measures. | 1992-04 |
|
| Effects of phaclofen and the enantiomers of baclofen on cardiovascular responses to intrathecal administration of L- and D-baclofen in the rat. | 1991-04-24 |
|
| Stereospecific actions of baclofen on sociosexual behavior, locomotor activity and motor execution. | 1989 |
|
| Potential involvement of a baclofen-sensitive autoreceptor in the modulation of the release of endogenous GABA from rat brain slices in vitro. | 1988-03 |
|
| Stereoselectivity of spinal neurotransmission: effects of baclofen enantiomer on tail-flick reflex in rats. | 1984 |
|
| Effects of intravenously administered enantiomers of baclofen on functionally identified units in lumbar dorsal horn of the spinal cat. | 1982-11 |
|
| The biological activity of d- and l-baclofen (Lioresal). | 1978-11-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:59:44 GMT 2025
by
admin
on
Mon Mar 31 17:59:44 GMT 2025
|
| Record UNII |
3OHN4989XM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Mon Mar 31 17:59:44 GMT 2025 , Edited by admin on Mon Mar 31 17:59:44 GMT 2025
|
||
|
FDA ORPHAN DRUG |
45690
Created by
admin on Mon Mar 31 17:59:44 GMT 2025 , Edited by admin on Mon Mar 31 17:59:44 GMT 2025
|
||
|
FDA ORPHAN DRUG |
65592
Created by
admin on Mon Mar 31 17:59:44 GMT 2025 , Edited by admin on Mon Mar 31 17:59:44 GMT 2025
|
||
|
FDA ORPHAN DRUG |
57391
Created by
admin on Mon Mar 31 17:59:44 GMT 2025 , Edited by admin on Mon Mar 31 17:59:44 GMT 2025
|
||
|
FDA ORPHAN DRUG |
109397
Created by
admin on Mon Mar 31 17:59:44 GMT 2025 , Edited by admin on Mon Mar 31 17:59:44 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
66514-99-6
Created by
admin on Mon Mar 31 17:59:44 GMT 2025 , Edited by admin on Mon Mar 31 17:59:44 GMT 2025
|
PRIMARY | |||
|
3OHN4989XM
Created by
admin on Mon Mar 31 17:59:44 GMT 2025 , Edited by admin on Mon Mar 31 17:59:44 GMT 2025
|
PRIMARY | |||
|
44600
Created by
admin on Mon Mar 31 17:59:44 GMT 2025 , Edited by admin on Mon Mar 31 17:59:44 GMT 2025
|
PRIMARY | |||
|
DB12098
Created by
admin on Mon Mar 31 17:59:44 GMT 2025 , Edited by admin on Mon Mar 31 17:59:44 GMT 2025
|
PRIMARY | |||
|
C90891
Created by
admin on Mon Mar 31 17:59:44 GMT 2025 , Edited by admin on Mon Mar 31 17:59:44 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
